These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35273234)

  • 21. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
    Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
    PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal Associations of the SARS-CoV-2 NP Antigen and Anti-Spike Total Ig Levels with Laboratory Parameters in a Greek Cohort of Hospitalized COVID-19 Patients.
    Rouka E; Kotsiou OS; Perlepe G; Pagonis A; Pantazopoulos I; Gourgoulianis KI
    Can Respir J; 2021; 2021():6590528. PubMed ID: 34621457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
    Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
    Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
    Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
    Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.
    Dhakal S; Ruiz-Bedoya CA; Zhou R; Creisher PS; Villano JS; Littlefield K; Ruelas Castillo J; Marinho P; Jedlicka AE; Ordonez AA; Bahr M; Majewska N; Betenbaugh MJ; Flavahan K; Mueller ARL; Looney MM; Quijada D; Mota F; Beck SE; Brockhurst J; Braxton AM; Castell N; Stover M; D'Alessio FR; Metcalf Pate KA; Karakousis PC; Mankowski JL; Pekosz A; Jain SK; Klein SL;
    mBio; 2021 Aug; 12(4):e0097421. PubMed ID: 34253053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
    Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
    Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.
    Racine T; Denizot M; Pannetier D; Nguyen L; Pasquier A; Raoul H; Saluzzo JF; Kobinger G; Veas F; Herbreteau CH
    J Infect Dis; 2019 Jun; 220(1):41-45. PubMed ID: 30852585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality.
    Hähnel V; Peterhoff D; Bäuerlein V; Brosig AM; Pamler I; Johnson C; Bica A; Totir M; Ossner T; Stemmer B; Toelge M; Schütz A; Niller HH; Schmidt B; Wagner R; Gessner A; Burkhard R; Offner R
    PLoS One; 2020; 15(12):e0243967. PubMed ID: 33351831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic Efficacy of Equine Immunoglobulin F(ab')
    Liu J; Zhang Z; Bai A; Sha Y; Ma L; Qin S; Chen F; Qin S; Wu J
    Appl Biochem Biotechnol; 2021 Oct; 193(10):3151-3162. PubMed ID: 34086256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
    Luczkowiak J; Radreau P; Nguyen L; Labiod N; Lasala F; Veas F; Herbreteau CH; Delgado R
    J Infect Dis; 2022 Dec; 227(1):35-39. PubMed ID: 35921532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equine immunoglobulin F(ab')
    Cui Z; Li D; Yi S; Guo Y; Dong G; Niu J; Zhao H; Zhang Y; Zhang S; Cao L; Wang K; Zhao Y; Hu G
    Int Immunopharmacol; 2019 Oct; 75():105714. PubMed ID: 31352323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.